0001209191-24-000371.txt : 20240103 0001209191-24-000371.hdr.sgml : 20240103 20240103162355 ACCESSION NUMBER: 0001209191-24-000371 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ryan Jason CENTRAL INDEX KEY: 0001585017 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39482 FILM NUMBER: 24506870 MAIL ADDRESS: STREET 1: C/O FOUNDATION MEDICINE, INC. STREET 2: ONE KENDALL SQUARE, SUITE B3501 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GeneDx Holdings Corp. CENTRAL INDEX KEY: 0001818331 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 851966622 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 8TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 617 780 8742 MAIL ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 8TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Sema4 Holdings Corp. DATE OF NAME CHANGE: 20210721 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences, Inc. DATE OF NAME CHANGE: 20200715 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-31 0 0001818331 GeneDx Holdings Corp. WGS 0001585017 Ryan Jason C/O GENEDX HOLDINGS CORP. 333 LUDLOW ST, NORTH TOWER STAMFORD CT 06902 1 1 0 0 Executive Chairman 0 Class A Common Stock 2023-12-31 4 M 0 67780 0.00 A 73614 D Class A Common Stock 114742 I By Jason Ryan Trust u/a dtd 11/25/2018 Restricted Stock Unit 2023-12-31 4 M 0 21780 0.00 D Class A Common Stock 21780 0 D Restricted Stock Unit 2023-12-31 4 M 0 46000 0.00 D Class A Common Stock 46000 0 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. 100% of the underlying awards shall become vested on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. /s/ Devin Schaffer, Attorney-in-Fact 2024-01-03